PriceTargets.com logo

Larimar Therapeutics - LRMR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.43
  • Forecasted Upside: 409.44%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 10 Buy Ratings
  • 1 Strong Buy Ratings
$4.01 As of 12/20/2024 06:40 PM ET
▲ +0.03 (0.75%)

This chart shows the closing price for LRMR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Larimar Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LRMR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LRMR

Analyst Price Target is $20.43
▲ +409.44% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Larimar Therapeutics in the last 3 months. The average price target is $20.43, with a high forecast of $26.00 and a low forecast of $14.00. The average price target represents a 409.44% upside from the last price of $4.01.

This chart shows the closing price for LRMR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 11 contributing investment analysts is to buy stock in Larimar Therapeutics. This rating has held steady since October 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
11/19/2024William BlairReiterated RatingOutperform
11/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
10/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
10/16/2024OppenheimerInitiated CoverageOutperform$26.00
10/3/2024WedbushInitiated CoverageOutperform$22.00
10/2/2024HC WainwrightInitiated CoverageBuy$15.00
9/4/2024Baird R WUpgradeStrong-Buy
9/4/2024Robert W. BairdInitiated CoverageOutperform$16.00
5/31/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$25.00 ➝ $25.00
5/22/2024CitigroupBoost TargetBuy ➝ Buy$10.00 ➝ $14.00
5/21/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$25.00
4/3/2024Leerink PartnrsReiterated RatingOutperform
4/3/2024Leerink PartnersInitiated CoverageOutperform$25.00
3/15/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$25.00
2/20/2024Lifesci CapitalReiterated RatingOutperform
2/13/2024CitigroupBoost TargetBuy ➝ Buy$4.50 ➝ $10.00
2/13/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$17.00 ➝ $25.00
11/17/2023CitigroupUpgradeNeutral ➝ Buy$4.50
8/15/2023William BlairReiterated RatingOutperform
8/15/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$17.00
5/18/2023CitigroupLower Target$7.00 ➝ $4.50
5/17/2023GuggenheimBoost Target$12.00 ➝ $14.00
3/15/2023GuggenheimReiterated RatingBuy$12.00
12/13/2022CitigroupInitiated CoverageNeutral$4.00
10/19/2022GuggenheimInitiated CoverageBuy$12.00
9/19/2022JMP SecuritiesBoost TargetMarket Outperform$10.00 ➝ $16.00
9/19/2022William BlairUpgradeMarket Perform ➝ Outperform
8/12/2022Lifesci CapitalUpgradeMarket Perform ➝ Outperform
2/16/2022Lifesci CapitalDowngradeOutperform ➝ Market Perform$3.00
2/15/2022JMP SecuritiesLower TargetBuy$30.00 ➝ $8.00
2/15/2022William BlairDowngradeOutperform ➝ Market Perform
8/4/2021Lifesci CapitalReiterated RatingOutperform
5/26/2021JMP SecuritiesLower TargetHold ➝ Outperform$43.00 ➝ $30.00
2/10/2021JMP SecuritiesInitiated CoverageOutperform
2/1/2021William BlairInitiated CoverageOutperform ➝ Outperform$29.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 8 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 7 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 9 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 9 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Larimar Therapeutics logo
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
Read More

Today's Range

Now: $4.01
Low: $3.87
High: $4.17

50 Day Range

MA: $6.91
Low: $3.98
High: $9.29

52 Week Range

Now: $4.01
Low: $3.01
High: $13.68

Volume

1,139,855 shs

Average Volume

628,800 shs

Market Capitalization

$255.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Frequently Asked Questions

What sell-side analysts currently cover shares of Larimar Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Larimar Therapeutics in the last twelve months: Baird R W, Citigroup Inc., HC Wainwright, JMP Securities, Leerink Partners, Leerink Partnrs, Lifesci Capital, Oppenheimer Holdings Inc., Robert W. Baird, Wedbush, and William Blair.
View the latest analyst ratings for LRMR.

What is the current price target for Larimar Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Larimar Therapeutics in the last year. Their average twelve-month price target is $20.43, suggesting a possible upside of 409.4%. Oppenheimer Holdings Inc. has the highest price target set, predicting LRMR will reach $26.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $14.00 for Larimar Therapeutics in the next year.
View the latest price targets for LRMR.

What is the current consensus analyst rating for Larimar Therapeutics?

Larimar Therapeutics currently has 10 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LRMR will outperform the market and that investors should add to their positions of Larimar Therapeutics.
View the latest ratings for LRMR.

What other companies compete with Larimar Therapeutics?

Other companies that are similar to Larimar Therapeutics include Bicycle Therapeutics, Avadel Pharmaceuticals, Septerna, Collegium Pharmaceutical and Bicara Therapeutics. Learn More about companies similar to Larimar Therapeutics.

How do I contact Larimar Therapeutics' investor relations team?

Larimar Therapeutics' physical mailing address is THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA, 19004. The company's listed phone number is (844) 511-9056 and its investor relations email address is [email protected]. The official website for Larimar Therapeutics is larimartx.com. Learn More about contacing Larimar Therapeutics investor relations.